GT Biopharma, Inc., an immuno-oncology biotechnology company focused on treatments based on its NK-engager and Bispecific Antibody Drug Conjugate platforms, has completed a restructuring of its management team.

Anthony J Cataldo has been named chairman and chief executive officer. Mr. Cataldo founded and served as chairman and chief executive officer at Iovance Biotherapeutics, Inc. with assets purchased from the National Cancer Institute (NCI). Iovance has a market capitalization more than $1.3 billion. 

Mr. Cataldo is the founder of GT Biopharma, Inc. He served as chairman and chief executive officer from July 2014 through April 2018. Mr. Cataldo founded GT Biopharma on the NK cell technology created for the treatment of solid and liquid tumors. Currently, two FDA clinical trials are underway for the NK cell technology. 

Mr. Cataldo said, “Our TriKe license from the University of Minnesota has continued to progress and we look forward to bringing you news of our TriKe technology assets in the very near future. The new management team finds itself at the same inflection point that Iovance was in when the company made the transition to a NASDAQ company that continues to have a bright future.”

Mr. Steven Weldon has been appointed as chief financial officer and a member of the Board of Directors. Mr. Weldon has 16 years of financial and accounting experience, most recently serving on the board at GT Biopharma and becoming CFO in 2014, holding both positions through October 2018.